Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.

by Sheriza N Baksh, Jodi B Segal, Mara McAdams-DeMarco, Rita R Kalyani, G Caleb Alexander, Stephan Ehrhardt
Published 2020-01-01

Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study

by Sheriza Baksh, Jiajun Wen, Omar Mansour, Hsien-Yen Chang, Mara McAdams-DeMarco, Jodi B. Segal, Stephan Ehrhardt, G. Caleb Alexander
Published 2021-08-01